免疫激活产品在瘤学中的第一次人体剂量选择的药理动力学模型
Haleh Saber1, Matthew D Thompson1, John K Leighton1
1US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncologic Diseases, 10903 New Hampshire Ave, Silver Spring, MD, 20903, United States.
简单的药理动力学 (PK) 建模可用于选择免疫瘤学药物的首次人体 (FIH) 剂量. 仔细选择变量至关重要,特别是对于CD3结构,以确保安全和最佳的FIH剂量选择.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
- 在瘤学瘤学.
背景情况:
- 药理动力学 (PK) 模型越来越多地被FDA用于免疫瘤学产品的首次人体 (FIH) 剂量选择.
- 评估简单的PK建模 (SPM) 使用清除剂量估计的适用性对于药物开发至关重要.
研究的目的:
- 评估SPM在免疫瘤学产品中的FIH剂量选择中的可接受性.
- 为了将SPM预测的FIH剂量与安全地给患者的剂量进行比较.
主要方法:
- 使用SPM计算的FIH剂量与CD3构造的特定参数 (例如,60公斤体重,0.75清除指数).
- 分析了免疫激活单克隆抗体 (mAbs) 对清除指数和体重变化的敏感性.
- 评估了体外EC50对PD-1/PD-L1mAbsFIH剂量选择的影响,并引用了相关产品的临床数据.
主要成果:
- 对于FIH剂量估计,SPM是可以接受的,但变量选择需要仔细考虑CD3结构.
- 基于活性试验的0.75清除指数和向血度被证明可以接受CD3结构.
- 0.85的缩放因子是可疑的,导致FIH剂量太接近一个产品预期的生物活性剂量.
- 免疫激活的mAbs对清除指数 (0.75-0.85) 或体重 (60-70公斤) 的变化表现出最小的敏感性.
- 对于PD-1/PD-L1 mAbs的体外EC50值导致了低于最佳的FIH剂量;相关产品临床数据为选择提供了信息.
- 提交的PK模型在方法,假设和变量方面表现出多样性,在某些情况下产生非最佳FIH剂量.
结论:
- 简单的PK建模可以接受在免疫瘤学FIH剂量选择,只要变量是明智地选择.
- 特定的参数选择 (例如体重,清除指数) 对CD3结构至关重要,以确保适当的FIH剂量选择.
- 仅仅在体外数据的使用可能会导致某些抗体类型 (例如PD-1/PD-L1 mAbs) 的FIH剂量低于最佳水平,因此需要整合相关产品的临床数据.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Analysis of Population Pharmacokinetic Data
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Model Approaches for Pharmacokinetic Data: Physiological Models
